Needham analyst Serge Belanger has maintained their bullish stance on VRDN stock, giving a Buy rating today.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Serge Belanger has given his Buy rating due to a combination of factors tied to Viridian Therapeutics’ robust 2026 catalyst calendar and advancing pipeline. He highlights that pivotal Phase 3 REVEAL data for elegrobart in both active and chronic thyroid eye disease (TED) are expected in the first half of 2026, positioning the asset as a potentially convenient, self-administered subcutaneous treatment dosed every four or eight weeks. In parallel, veligrotug is under Priority Review with an FDA decision targeted for June 30, 2026, creating a clear regulatory milestone that could unlock meaningful value. Belanger also notes that the back half of 2026 will likely be driven by the U.S. launch of veligrotug if approved, alongside key development decisions in the company’s FcRn portfolio.
He additionally points to Viridian’s pipeline expansion, including a newly announced half‑life extended subcutaneous TSH receptor antibody aimed at Graves’ disease and TED, which is slated to reach IND filing late in 2026 and underscores the company’s longer‑term growth potential. From a financial standpoint, he emphasizes that Viridian’s approximately $888 million in cash (as of October 31, 2025) is expected to support operations through profitability, reducing financing risk. Finally, he underscores that veligrotug could offer a more attractive therapy versus the current TED standard of care, with a regimen requiring fewer infusions and shorter administration time, which may support strong commercial uptake. Taken together, these clinical, regulatory, commercial, and financial elements underpin his positive view and support the Buy recommendation on VRDN.
According to TipRanks, Belanger is a 5-star analyst with an average return of 13.0% and a 50.99% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Cytokinetics, and BioCryst.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.